靶碘联合:进展期分化型甲状腺癌治疗新策略  

Combination of targeted multikinase inhibitor and radioiodine:a new strategy of treatment for advanced differen⁃tiated thyroid carcinoma

作　　者：柳卫[1] LIU Wei(Department of Nuclear Medicine,The First Affiliated Hospital with Nanjing Medical University,Jiangsu Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院核医学科,江苏南京210029

出　　处：《外科理论与实践》2023年第6期520-523,共4页Journal of Surgery Concepts & Practice

基　　金：国家自然科学基金(81771870)。

摘　　要：进展期分化型甲状腺癌缺乏有效的治疗方案、总体预后较差,是临床亟需解决的难题。多靶点酪氨酸激酶抑制剂已获批应用于放射性碘难治性分化型甲状腺癌的治疗,最近也被推荐用于局部进展期分化型甲状腺癌术前新辅助治疗。虽然放射性碘治疗是进展期分化型甲状腺癌术后的标准治疗方案,但存在一定的局限性和限制。多靶点酪氨酸激酶抑制剂联合放射性碘治疗,有望成为进展期分化型甲状腺癌治疗的新策略。Advanced differentiated thyroid carcinoma(ADTC)lacks effective treatment options,and has a poor prognosis,which is an urgent clinical problem to be resolved.Targeted multikinase inhibitor(MKI)has been approved for the treatment of radioiodine refractory differentiated thyroid carcinoma,and have recently been recommended as a preoperative neoadjuvant therapy agents for locally ADTC.Although radioiodine therapy is the standard postoperative treatment for ADTC,it has certain limitations.MKI combined with radioiodine therapy is expected to become a new strategy of treatment for ADTC.

关 键 词：进展期分化型甲状腺癌 多靶点激酶抑制剂 放射性碘 碘-131 

分 类 号：R736.1[医药卫生—肿瘤]